Cyberonics Formal Request to CMS to Consider VNS for TRD
July 24, 2006 Cyberonics Formal Request to CMS to Consider VNS for TRD Cyberonics, Inc., has requested that the Centers for Medicare and Medicaid Services reconsider the existing National Coverage Decision 160.18 and add the Cyberonics' vagus nerve stimulation (VNS) device as covered durable medical equipment for patients diagnosed with treatment resistant depression (TRD). Support for this request includes the July 15, 2006, U.S. Food and Drug Administration expansion of indications for use of VNS therapy for patients with TRD. Also, cited are results of a seven-year clinical trial program in which the Center for Devices and . . .
